Fig 1.
Axial T2-weighted MR imaging of mice with tumors.
Representative axial MR images of mice pre-therapy (A, B) or two weeks after initiation of therapy (C, D) with vehicle (A, C) or bevacizumab (B, D). Axial T1 maps of the same tumors (E, F, G, H). Representative axial MR images of mice pre-therapy (E, F) or two weeks after initiation of therapy (G, H) with vehicle (E, G) or bevacizumab (F, H).
Fig 2.
Tumor weight derived from MR images before and two weeks after initiation of therapy, and, by necropsy two weeks after initiation of therapy. *, p<.05. Error bars represent standard deviation.
Fig 3.
Correlation of tumor weight by MR and ex vivo.
Fig 4.
T1 values pre and post therapy.
T1 values of tumors pre, 48 hour, and two weeks post therapy. *, p<.05. Error bars represent standard deviation.
Fig 5.
Histologic analysis of mean vessel density, proliferation, and apoptosis 2 weeks post-initiation of therapy.
A) Immunohistochemical staining for CD31 (left) and microvessel density (right). B) Immunohistochemical staining for Ki67 (left) and Ki67 labelling index (right). C) TUNEL staining (left) and apoptotic index (right). Error bars represent standard deviation.